Esperion Therapeutics ESPR reported its Q2 earnings results on Tuesday, August 2, 2022 at 07:00 AM.
Here's what investors need to know about the announcement.
Earnings
Esperion Therapeutics missed estimated earnings by 12.9%, reporting an EPS of $-1.05 versus an estimate of $-0.93.
Revenue was down $21.82 million from the same period last year.
Past Earnings Performance
Last quarter the company beat on EPS by $0.11 which was followed by a 2.3% drop in the share price the next day.
Here's a look at Esperion Therapeutics's past performance:
Quarter | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 |
---|---|---|---|---|
EPS Estimate | -1.04 | -2.27 | -2.79 | -1.84 |
EPS Actual | -0.93 | -1.77 | -2.62 | -1.67 |
Revenue Estimate | 15.39M | 14.47M | 12.85M | 42.27M |
Revenue Actual | 18.84M | 15.40M | 14.41M | 40.66M |
To track all earnings releases for Esperion Therapeutics visit their earnings calendar here.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.